       Document 0092
 DOCN  M95B0092
 TI    Measurement by the polymerase chain reaction of the Epstein-Barr virus
       load in infectious mononucleosis and AIDS-related non-Hodgkin's
       lymphomas.
 DT    9511
 AU    Laroche C; Drouet EB; Brousset P; Pain C; Boibieux A; Biron F; Icart J;
       Denoyel GA; Niveleau A; Unite d'infectiologie, Institut Pasteur de Lyon,
       France.
 SO    J Med Virol. 1995 May;46(1):66-74. Unique Identifier : AIDSLINE
       MED/95348673
 AB    A polymerase chain reaction (PCR) assay for the detection of
       Epstein-Barr virus (EBV) sequences in various clinical samples,
       especially peripheral blood leukocytes (PBL) and serum, was carried out
       and the results obtained were compared with specific EBV serology. One
       hundred seventy patients were enrolled in the study: 89 healthy blood
       donors, 22 asymptomatic patients, 36 individuals with primary EBV
       infection (including 19 patients with infectious mononucleosis [IM]), 22
       HIV-infected subjects (including 4 with hairy oral leukoplakia, 3 with
       central nervous disorders, and 15 with non-Hodgkin's lymphoma). All the
       serum samples from the healthy blood donors were negative. In patients
       with IM and in AIDS-non Hodgkin's lymphoma (ARNHL), PCR was strongly
       positive in leukocytes (> 2,000 genome equivalents/10(4) cells), which
       was correlated with detectable amounts of EBV DNA in serum. The overall
       positivity rate of PCR in serum was 58.8%, 68%, and 73% of cases for
       non-IM primary EBV infections, IM, and ARNHL, respectively. In two cases
       of EBV primary infection, the viral DNA was detected in serum,
       respectively 1 month and 2 months before IgM positivity and IgG rise. In
       one case of ARNHL followed up for several months, PCR (viral load of
       2,000 genome equivalents/10(4) cells) became positive concurrently with
       appearance of lymphoma. In immunocompromised individuals, PCR EBV, if
       carried out in larger prospective studies, could be considered as a
       tumor marker, useful for predicting EBV-driven lymphoma and follow-up
       therapy.
 DE    Acquired Immunodeficiency Syndrome/VIROLOGY  Adult  Base Sequence  Cell
       Line  DNA, Viral/ANALYSIS  Female  Herpesvirus 4, Human/*GENETICS  Human
       Infectious Mononucleosis/DIAGNOSIS/*VIROLOGY  Leukocytes,
       Mononuclear/VIROLOGY  Lymphoma, AIDS-Related/DIAGNOSIS/*VIROLOGY  Male
       Middle Age  Molecular Sequence Data  Polymerase Chain Reaction/*METHODS
       Retrospective Studies  Saliva/VIROLOGY  Sensitivity and Specificity
       Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

